Nicotinamide phosphoribosyltransferase (NAMPT) is an enzyme that helps to regulate and reprogram cellular metabolism, and control the activity of NAD-dependent enzymes. In particular, NAMPT sets intracellular NAD levels. A decline in NAD levels is associated with many metabolic and age-related diseases. University of Pittsburgh researchers have developed novel methods and materials for increasing NAMPT activity levels to treat hepatosteatosis, insulin resistance syndromes and/or their associated manifestations, obesity, sarcopenia, disorders of inflammation, autoimmune conditions, skin aging, cardiovascular diseases (e.g., heart failure), acute and/or chronic kidney injury, and cognitive decline. These methods may also help reduce the likelihood of developing skin cancer.
Description
The methods and materials for increasing NAMPT activity can be used to increase NAD+ levels to slow cognitive decline, vision loss, and/or hearing loss as well as to prolong lifespan. Pitt researchers created a critical document that outlines compounds having the ability to increase NAMPT activity within cells and/or within a mammal, and also methods for treating mammals having a condition responsive to an increase of NAMPT activity.
Applications
• Treating Hepatosteatosis, insulin resistance syndromes
• Obesity, sarcopenia, inflammation disorders
• Age-related cognitive decline
• Autoimmune conditions, skin aging, cardiovascular diseases
• Acute or chronic kidney injury, and infertility
• Reducing the likelihood of developing skin cancer
Advantages
• Compounds can increase NAMPT activity within cells and/or within a mammal
• Humans having various conditions including cardiovascular disease show improvement with increase of NAMPT activity
Invention Readiness
In vitro
IP Status
https://patents.google.com/patent/US20230310424A1
